News | 28 September 2021
Bal Pharma ramps up API capacity of Gliclazide
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus
It is a recombinant nanoparticle protein-based vaccine
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
The company is the Clinical Research Organisation of Caplin Point Laboratories
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
The bank will provide a complete range of financing options including hospitals, labs, diagnostic centres and equipment manufacturers
The purchaser is a part of the portfolio companies of PE firm True North. The said transaction is not a related party transaction.
The company said in a regulatory filing that it was confident of addressing the observations satisfactorily
.jpg)
The council has also reduced the GST to 5 per cent on a few more Covid-19 medicines
This award is open to all currently operational laboratories pertaining to testing, calibration & medical including their proficiency testing providers & reference material producers located in India
.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
.jpg)
In the period April to August 2021, exports stood at Rs 73,469.29 crores compared to Rs 72,275.22 crores for the period April to August 2020 a growth of 1.65 per cent
The Lancet study said that Sputnik Light showed 78.6 to 83.7 per cent efficacy against Covid-19, significantly higher than most two-shot vaccines
The board has approved the settlement of US $ 248 million towards Direct Purchaser group and Retailer Opt-Out group subject to court approval
The amalgamation is expected to bring in a lot of synergies in terms of operational efficiency and productivity for the combined entity
The order strengthens the company’s position in the East African market
These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients
.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
Research collaboration covers multiple antibody research programs
Subscribe To Our Newsletter & Stay Updated
